{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:13:13Z","timestamp":1787242393421,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["DK 46335"],"award-info":[{"award-number":["DK 46335"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011770","name":"Skaggs Institute for Chemical Biology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012133","name":"Lita Annenberg Hazen Foundation (JWK)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012133","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010249","name":"Indiana University School of Medicine, Department of Biochemistry and Molecular Biology (SMJ)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010249","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hewitt Foundation"},{"DOI":"10.13039\/100006206","name":"Department of Energy, Office of Biological and Environmental Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006206","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Institutes of Health, National Center for Research Resources, Biomedical Technology Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.bmcl.2017.05.080","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T20:15:15Z","timestamp":1496088915000},"page":"3441-3449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors"],"prefix":"10.1016","volume":"27","author":[{"given":"Stephen","family":"Connelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Mortenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwook","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian A.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan T.","family":"Powers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery W.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2017.05.080_b0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00002281-200401000-00013","article-title":"The systemic amyloidoses","volume":"16","author":"Buxbaum","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0010","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bmcl.2017.05.080_b0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1056\/NEJM199702133360703","article-title":"Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2017.05.080_b0020","doi-asserted-by":"crossref","first-page":"14943","DOI":"10.1073\/pnas.261419998","article-title":"The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis","volume":"98","author":"Jiang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/ndt\/13.suppl_7.33","article-title":"Human brain amyloidoses","volume":"13","author":"Gambetti","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.bmcl.2017.05.080_b0030","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","article-title":"Fibril in senile systemic amyloidosis is derived from normal transthyretin","volume":"87","author":"Westermark","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0035","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1212\/WNL.58.7.1001","article-title":"Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity","volume":"58","author":"Ikeda","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.bmcl.2017.05.080_b0040","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/01.LAB.0000059937.11023.1F","article-title":"Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology","volume":"83","author":"Sekijima","year":"2003","journal-title":"Lab Invest"},{"key":"10.1016\/j.bmcl.2017.05.080_b0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ajmg.1320600606","article-title":"Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal)","volume":"60","author":"Sousa","year":"1995","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.bmcl.2017.05.080_b0050","doi-asserted-by":"crossref","first-page":"13527","DOI":"10.1021\/bi00041a032","article-title":"Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease","volume":"34","author":"McCutchen","year":"1995","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2017.05.080_b0055","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/bi027319b","article-title":"D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?","volume":"42","author":"Hammarstrom","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2017.05.080_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cell.2005.01.018","article-title":"The biological and chemical basis for tissue selective amyloid disease","volume":"121","author":"Sekijima","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.bmcl.2017.05.080_b0065","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/10408369409084679","article-title":"Amyloidosis","volume":"31","author":"Sipe","year":"1994","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.bmcl.2017.05.080_b0070","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","article-title":"Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations","volume":"10","author":"Westermark","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.bmcl.2017.05.080_b0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","article-title":"The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug","volume":"421","author":"Johnson","year":"2012","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0080","series-title":"Protein Misfolding Diseases: Current and Emerging Principles and Therapies","first-page":"967","article-title":"Understanding and ameliorating the transthyretin amyloidoses","author":"Johnson","year":"2010"},{"key":"10.1016\/j.bmcl.2017.05.080_b0085","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature02261","article-title":"Protein folding and misfolding","volume":"426","author":"Dobson","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2017.05.080_b0090","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nature02264","article-title":"Folding proteins in fatal ways","volume":"426","author":"Selkoe","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2017.05.080_b0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-440X(96)80089-3","article-title":"Alternative conformations of amyloidogenic proteins govern their behavior","volume":"6","author":"Kelly","year":"1996","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0100","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1532-5415.2011.03868.x","article-title":"Transthyretin cardiac amyloidoses in older North Americans","volume":"60","author":"Dharmarajan","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bmcl.2017.05.080_b0105","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1600-0420.2007.01098.x","article-title":"Ocular manifestations in liver transplant recipients with familial amyloid polyneuropathy","volume":"86","author":"Sandgren","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0110","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00595-010-4488-5","article-title":"Manifestations of transthyretin-related familial amyloidotic polyneuropathy: long-term follow-up of Japanese patients after liver transplantation","volume":"41","author":"Ohya","year":"2011","journal-title":"Surg Today"},{"key":"10.1016\/j.bmcl.2017.05.080_b0115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","article-title":"Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments","volume":"86","author":"Sekijima","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bmcl.2017.05.080_b0120","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1750-1172-8-31","article-title":"Guideline of transthyretin-related hereditary amyloidosis for clinicians","volume":"8","author":"Ando","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.bmcl.2017.05.080_b0125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1212\/WNL.0000000000003001","article-title":"Cerebral amyloid angiopathy in posttransplant patients with hereditary ATTR amyloidosis","volume":"87","author":"Sekijima","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.bmcl.2017.05.080_b0130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"Maia","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.bmcl.2017.05.080_b0135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1126\/science.1079589","article-title":"Prevention of transthyretin amyloid disease by changing protein misfolding energetics","volume":"299","author":"Hammarstrom","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2017.05.080_b0140","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1021\/ar020073i","article-title":"Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses","volume":"38","author":"Johnson","year":"2005","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmcl.2017.05.080_b0145","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1021\/ja042929f","article-title":"Kinetic stabilization of an oligomeric protein by a single ligand binding event","volume":"127","author":"Wiseman","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.05.080_b0150","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jmb.2005.01.050","article-title":"Kinetic stabilization of the native state by protein engineering: Implications for inhibition of transthyretin amyloidogenesis","volume":"347","author":"Foss","year":"2005","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0155","doi-asserted-by":"crossref","first-page":"15525","DOI":"10.1021\/bi051608t","article-title":"The pathway by which the tetrameric protein transthyretin dissociates","volume":"44","author":"Foss","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2017.05.080_b0160","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.bmcl.2017.05.080_b0165","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0170","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/74082","article-title":"Rational design of potent human transthyretin amyloid disease inhibitors","volume":"7","author":"Klabunde","year":"2000","journal-title":"Nat Struct Biol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0175","doi-asserted-by":"crossref","first-page":"15051","DOI":"10.1073\/pnas.93.26.15051","article-title":"Inhibiting transthyretin amyloid fibril formation via protein stabilization","volume":"93","author":"Miroy","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-894X(98)00696-9","article-title":"Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors","volume":"9","author":"Oza","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.05.080_b0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1021\/jm010257n","article-title":"Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors","volume":"45","author":"Oza","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0190","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0968-0896(98)00130-8","article-title":"Discovering transthyretin amyloid fibril inhibitors by limited screening","volume":"6","author":"Baures","year":"1998","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0195","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0968-0896(99)00066-8","article-title":"Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid","volume":"7","author":"Baures","year":"1999","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0200","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/jm030347n","article-title":"Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis","volume":"47","author":"Adamski-Werner","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0205","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3700059","article-title":"Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants","volume":"84","author":"Miller","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.bmcl.2017.05.080_b0210","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.chembiol.2004.10.009","article-title":"Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity","volume":"11","author":"Purkey","year":"2004","journal-title":"Chem Biol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0215","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1002\/anie.200351179","article-title":"Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action","volume":"42","author":"Razavi","year":"2003","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmcl.2017.05.080_b0220","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.bmcl.2004.12.022","article-title":"Design, synthesis, and evaluation of oxazole transthyretin amyloidogenesis inhibitors","volume":"15","author":"Razavi","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2017.05.080_b0225","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/ja993309v","article-title":"Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors","volume":"122","author":"Petrassi","year":"2000","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.05.080_b0230","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1021\/jm0708735","article-title":"Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors","volume":"51","author":"Johnson","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0235","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.1021\/jm800435s","article-title":"Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies","volume":"51","author":"Johnson","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0240","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1021\/jm801347s","article-title":"Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies","volume":"52","author":"Johnson","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0245","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/ja908562q","article-title":"A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity","volume":"132","author":"Choi","year":"2010","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.05.080_b0250","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.sbi.2009.12.009","article-title":"Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses","volume":"20","author":"Connelly","year":"2010","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.bmcl.2017.05.080_b0255","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1021\/jm049274d","article-title":"Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation","volume":"48","author":"Johnson","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0260","doi-asserted-by":"crossref","first-page":"14545","DOI":"10.1073\/pnas.0501609102","article-title":"Genistein, a natural product from soy, is a potent inhibitor of transthyretin amyloidosis","volume":"102","author":"Green","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0265","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1021\/ja030294z","article-title":"Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization","volume":"125","author":"Green","year":"2003","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.05.080_b0270","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1021\/ja044351f","article-title":"Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state","volume":"127","author":"Petrassi","year":"2005","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmcl.2017.05.080_b0275","doi-asserted-by":"crossref","first-page":"12956","DOI":"10.1073\/pnas.95.22.12956","article-title":"Inhibiting transthyretin conformational changes that lead to amyloid fibril formation","volume":"95","author":"Peterson","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0280","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1021\/bi952501g","article-title":"The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid","volume":"35","author":"Lai","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmcl.2017.05.080_b0285","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1073\/pnas.091431798","article-title":"Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma","volume":"98","author":"Purkey","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0290","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/clinchem\/43.7.1223","article-title":"Plasma protein abnormalities in nephrotic syndrome: effect on plasma colloid osmotic pressure and viscosity","volume":"43","author":"Joven","year":"1997","journal-title":"Clin Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0295","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.bmcl.2017.05.080_b0300","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/13506120600960882","article-title":"Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis","volume":"13","author":"Sekijima","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.bmcl.2017.05.080_b0305","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.neures.2006.08.014","article-title":"Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis","volume":"56","author":"Tojo","year":"2006","journal-title":"Neurosci Res"},{"key":"10.1016\/j.bmcl.2017.05.080_b0310","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJM198006123022403","article-title":"Amyloid deposits and amyloidosis: the beta-fibrilloses (second of two parts)","volume":"302","author":"Glenner","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2017.05.080_b0315","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/13506129.2014.997872","article-title":"Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis","volume":"22","author":"Sekijima","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.bmcl.2017.05.080_b0320","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1517\/13543784.2014.922541","article-title":"An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis","volume":"23","author":"Obici","year":"2014","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.bmcl.2017.05.080_b0325","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40120-015-0031-3","article-title":"A review of tafamidis for the treatment of transthyretin-related amyloidosis","volume":"4","author":"Waddington Cruz","year":"2015","journal-title":"Neurol Ther"},{"key":"10.1016\/j.bmcl.2017.05.080_b0330","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0335","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmcl.2017.05.080_b0340","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/jcc.20634","article-title":"A semiempirical free energy force field with charge-based desolvation","volume":"28","author":"Huey","year":"2007","journal-title":"J Comput Chem"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17305784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X17305784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:19:18Z","timestamp":1760771958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X17305784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":68,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0960894X17305784"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.05.080","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2017.05.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}